Novel targets for antidepressant therapies
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Most depressed patients fail to achieve remission despite adequate antidepressant monotherapy, and a substantial minority show minimal improvement despite optimal and aggressive therapy. However, major advances have taken place in elucidating the neurobiology of depression, and several novel targets for antidepressant therapy have emerged. Three primary approaches are currently being taken: 1) optimizing the pharmacologic modulation of monoaminergic neurotransmission, 2) developing medications that target neurotransmitter systems other than the monoamines, and 3) directly modulating neuronal activity via focal brain stimulation. We review novel therapeutic targets for developing improved antidepressant therapies, including triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, dopamine receptor agonists, corticotropin-releasing factor-1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, N-methyl-d-aspartate receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, and deep brain stimulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244
Self-citationDeep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression
Schlaepfer, T. E., Cohen, M. X., Frick, C., Kosel, M., Brodesser, D., Axmacher, N., Joe, A. Y., Kreft, M., Lenartz, D., & Sturm, V. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301408 · Cited by 1,027
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death
Sapolsky, R. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00971-9 · Cited by 699 · cited 1×
“Excitatory glutamatergic neurotransmission has been hypothesized to be involved in the pathophysiology of depression [39], and ionotropic receptor antagonists may attenuate stressinduced atrophy in hippocampal neurons in animals [ 40 ].”
BackgroundNemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627
Sackeim, H. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00271-8 · Cited by 568
Vagus-nerve stimulation for the treatment of epilepsy
Ben-Menachem, E. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00220-x · Cited by 560
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Lin, P.-Y., & Su, K.-P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0712 · Cited by 481
Kellner, C. H., Knapp, R. G., Petrides, G., Rummans, T. A., Husain, M. M., Rasmussen, K., Mueller, M., Bernstein, H. J., O’Connor, K., Smith, G., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1337 · Cited by 471
Glutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408
Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes
Nahas, Z., Marangell, L. B., Husain, M. M., Rush, A. J., Sackeim, H. A., Lisanby, S. H., Martinez, J. M., & George, M. S. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0902 · Cited by 390
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
George, M. S., Rush, A. J., Marangell, L. B., Sackeim, H. A., Brannan, S. K., Davis, S. M., Howland, R., Kling, M. A., Moreno, F., Rittberg, B., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.028 · Cited by 372 · cited 1×
“The antidepressant response to VNS plus TAU over 1 year was statistically signifi cantly greater than the response seen with TAU alone [ 72 ].”
ResultAn open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Avery, D. H., Holtzheimer, P. E., Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., Haynor, D. R., Claypoole, K. H., Wajdik, C., & Roy-Byrne, P. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.003 · Cited by 318
Self-citationSu, K.-P., Huang, S.-Y., Chiu, T.-H., Huang, K.-C., Huang, C.-L., Chang, H.-C., & Pariante, C. M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0418 · Cited by 308 · cited 1×
“Omega-3 fatty acids may have a role in treating perinatal depression [ 58 ], but results are mixed [59].”
BackgroundJiménez, F., Velasco, F., Salin-Pascual, R., Hernández, J. A., Velasco, M., Criales, J. L., & Nicolini, H. (2005) · Neurosurgery · doi:10.1227/01.neu.0000170434.44335.19 · Cited by 291
Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286 · cited 1×
“An initial placebo-controlled trial with aprepitant (MK-869; Merck & Co., Whitehouse Station, NJ) reported antidepressant effi cacy for this compound [31], but later studies failed to confi rm this [ 34 ].”
BackgroundRapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254 · cited 1×
“Another CRF 1 receptor antagonist (CP-316311; Pfi zer, Groton, CT) failed to show signifi cant antidepressant effects in a placebo- and sertraline-controlled trial [ 25 ]; whether the dose tested was suffi cient to block central nervous system CRF 1 receptors remains unclear.”
BackgroundDeep brain stimulation of the lateral habenula in treatment resistant major depression
Sartorius, A., & Henn, F. A. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2007.03.021 · Cited by 251
Dunner, D. L., Rush, A. J., Russell, J. M., Burke, M., Woodard, S., Wingard, P., & Allen, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0501 · Cited by 234 · cited 1×
“Also, the maintenance of response with VNS plus TAU [73] appears to be greater than that seen with TAU alone [ 74 ], although this has not been studied in a randomized, controlled fashion.”
MethodKeck, P. E., Mintz, J., McElroy, S. L., Freeman, M. P., Suppes, T., Frye, M. A., Altshuler, L. L., Kupka, R., Nolen, W. A., Leverich, G. S., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.056 · Cited by 234 · cited 1×
“Other placebo-controlled studies have found no antidepressant effects for omega-3 fatty acids, including EPA [ 56 ].”
BackgroundBystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220 · cited 1×
“Certain drugs in this class have been shown to be effective in augmenting SSRIs in certain anxiety disorders, such as obsessive-compulsive disorder [ 4 ] and post-traumatic stress disorder [5].”
BackgroundCorya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170 · cited 1×
“An olanzapine–fl uoxetine combination is FDA approved for treating bipolar depression [ 9 ].”
BackgroundMcIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140
Magnetic Seizure Therapy Improves Mood in Refractory Major Depression
Kosel, M., Frick, C., Lisanby, S. H., Fisch, H.-U., & Schlaepfer, T. E. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300293 · Cited by 136
Rees, A.-M., Austin, M.-P., & Parker, G. B. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701827267 · Cited by 134 · cited 1×
“Omega-3 fatty acids may have a role in treating perinatal depression [58], but results are mixed [ 59 ].”
ResultAnesthetic Considerations for Magnetic Seizure Therapy: A Novel Therapy for Severe Depression
White, P. F., Amos, Q., Zhang, Y., Stool, L., Husain, M. M., Thornton, L., Downing, M., McClintock, S., & Lisanby, S. H. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000221182.71648.a3 · Cited by 111
Keitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108 · cited 1×
“Risperidone was effective as an adjunct in SSRI nonresponders in two randomized, double-blind, placebocontrolled trials [16, 17 ].”
BackgroundSelf-citationRopinirole in treatment-resistant depression: a 16-week pilot study
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000612 · Cited by 73
Cited by
Bewernick, B. H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M. X., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.013 · Cited by 865
Targeted electrode-based modulation of neural circuits for depression.
Mayberg, H. S. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38454 · Cited by 542
“…is unlikely to be the result of injury or dysfunction of a single brain region but rather a system-wide disorder, in which interruption at specific sites or “nodes” within a defined functional circuit or network linking many brain regions can result in stereotypic depressive symptoms ( 9, 1 3).”
BackgroundThe impact of treatment on HPA axis activity in unipolar major depression
McKay, M. S., & Zakzanis, K. K. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.07.012 · Cited by 103
Metadata
- Authors
- Holtzheimer, P. E., & Nemeroff, C. B.
- Venue
- Current Psychiatry Reports
- Published
- 2008-12
- Volume
- 10
- Issue
- 6
- Pages
- 465-473
- ISSN
- 1523-3812 (ISSN-L)
- 1535-1645
- OpenAlex
- W2021969484
- Cited by
- 37
- References
- 36
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.